ASGCT2024 Poster - Qualification of a Preclinical to Phase I ELISpot Assay for AAV Immune Monitoring

2024asgct elispot

Qualification of a Preclinical to Phase I ELISpot Assay for AAV Immune Monitoring

This AmplifyBio poster describes a new method for identifying immune responses to AAV gene therapy using an ELISpot assay. This method is sensitive and requires fewer cells than other methods, making it a valuable tool for researchers. The study successfully qualified the method for use in both animals and humans, making it suitable for preclinical testing and clinical trials.

Contact Us

AmplifyBio couples dedicated testing and related CRO services with a skilled team and access to the latest resources. This combination produces groundbreaking research for specialty products and assessments that can be analyzed for implementation in products and processes. Talk with us about your individual requirements and work with our specialists to develop an effective solution.